Reply to Decroo et al.: High-Dose First-Line Treatment Regimen for Recurrent Rifampicin-Susceptible Tuberculosis

Affiliations

• ¹ Johns Hopkins University School of MedicineBaltimore, Maryland.
• ² Harvard T. H. Chan School of Public HealthBoston, Massachusetts.
• ³ TASK Applied Science Cape Town, South Africa.
• ⁴ Stellenbosch UniversityCape Town, South Africa.
• ⁵ National Institute of Allergy and Infectious DiseasesBethesda, Maryland.
• ⁶ Frontier Science and Technology Research FoundationAmherst, New York.
• ⁷ Social & Scientific Systems, Inc.Silver Spring, Marylandand.
• ⁸ University of Nebraska Medical CenterOmaha, Nebraska.